Stock listing
Evommune, Inc.
Selected listing: EVMN · BX · CHF · CH
Evommune, Inc. (BX Swiss: EVMN), Health Technology. Latest release Oct 1, 2026: Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating…
- Ticker
- BX Swiss: EVMN
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- BX Swiss
- Currency
- CHF
About Evommune, Inc.
Evommune, Inc. is a public company traded under the ticker EVMN in the American market. Evommune is committed to advancing its mission and enhancing shareholder value.
Latest news from Evommune, Inc.
Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
October 1, 2026
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress
September 23, 2026
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis
September 8, 2026
Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights
August 6, 2026
Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis
July 30, 2026